Asphalion participated in the 8th General Assembly Meeting of the iHIVARNA’s project.
The General Assembly meetings take place twice per year and include representatives from each partner of the iHIVARNA’s consortium.
The 8th General Assembly meeting focused on three main topics:
1-Review of the phase I clinical trial
2-Current status of the phase II clinical trial, and
3-Next actions to be taken
The meeting took place at the 400-years-old Saint-Louis Hospital in Paris. The iHIVARNA meeting took place on July 27th, after the 9th International AIDS Society (IAS) Conference on HIV Science, that was held between July 23rd and July 26th in the same city, and where most participants of the iHIVARNA consortium participated.
iHIVARNA was the first EU-funded project that Asphalion participated. The principal aim of iHIVARNA is to successfully immunize antiretroviral-treated HIV-infected patients with 3 injections of the candidate universal HIV-TriMix-mRNA as an mRNA-based therapeutic vaccine with the final objective of achieving a functional cure of HIV infection. Within the iHIVARNA consortium, Asphalion participates as a partner by developing and conducting the regulatory activities.
You can follow the project status and check for more information on www.ihivarna.org.
“The research leading to these results has received funding from the European Comunity’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 602570 – the iHIVARNA project.”
iHIVARNA: The research leading to this results has received funding from the European Comunity’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 602570 – the iHIVARNA project.
